Invitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos' B...
June 23 2016 - 1:33AM
Galapagos NV (Euronext & NASDAQ: GLPG) has the honor to
invite its Shareholders, Warrant Holders, Directors and Statutory
Auditor to its Special and Extraordinary Shareholders' Meetings
that will be held on Tuesday 26 July 2016 at 2 pm CET at
the offices of notary public Matthieu Derynck (Van Halteren,
associated notaries public, Rue de Ligne 13, 1000 Brussels).
Galapagos announces that Dr. Mary Kerr has been nominated to
join the Board of Directors of Galapagos, subject to shareholder
approval during the Special Shareholders' Meeting on 26 July 2016.
Dr. Kerr, a UK national, is Chief Executive Officer and
Director at NeRRe Therapeutics. Prior to her appointment at NeRRe,
Mary held a range of senior leadership roles at GSK over more than
20 years, most recently as Senior Vice President and Global
Franchise leader for the Immuno-inflammation and Infectious
Diseases franchise. Mary was a founding member and on the Corporate
Executive team of ViiV Healthcare where she led a turnaround in the
performance of the HIV business in Europe. She has spent the
majority of her career on the R&D commercial interface in
global strategy and regional operational roles, predominantly in
the specialty and orphan space. Mary gained a Ph.D. in Pharmacology
at the University of Bradford, did post-doctoral research at the
Michigan Cancer Foundation in Detroit and has an MBA from the
University of Kingston. She is also an Operating Partner with
Advent Life Sciences, one of NeRRe Therapeutics' investors, since
October 2015.
In order to be admitted to the Shareholders' Meetings, the
holders of securities issued by the Company must comply with
article 536 of the Belgian Companies Code and article 29 of the
Company's articles of association, and fulfill the formalities
described in the convening notices.
The convening notice and other documents pertaining to the
Shareholders' Meetings can be consulted at
www.glpg.com/shareholders-meetings.
About Galapagos Galapagos(Euronext & NASDAQ: GLPG) is
a clinical-stage biotechnology company specialized in the discovery
and development of small molecule medicines with novel modes of
action. Our pipeline comprises Phase 2, Phase 1, pre-clinical and
discovery studies in cystic fibrosis, inflammation, fibrosis,
osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring
this JAK1-selective inhibitor for inflammatory indications to
patients all over the world. Galapagos is focused on the
development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including
fee-for-service subsidiary Fidelta, has approximately 440
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Contacts
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn Fox |
VP IR
& Corporate Communications +1 781 460 1784 |
Director Communications
+31 6 53 591 999 communications@glpg.com |
Paul van der Horst Director IR & Business Development +31 6 53
725 199 |
|
ir@glpg.com |
|
Forward-looking statements This release may contain
forward-looking statements. Such forward-looking statements are not
guarantees of future results. These forward-looking statements
speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any
forward-looking statements in this document, unless specifically
required by law or regulation.
Invitation to EGM and nomination Mary Kerr
http://hugin.info/133350/R/2022669/751483.pdf
HUG#2022669
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024